AZN [NASD]
AstraZeneca PLC
Index- P/E- EPS (ttm)-0.42 Insider Own0.50% Shs Outstand3.10B Perf Week-2.47%
Market Cap197.49B Forward P/E13.03 EPS next Y4.96 Insider Trans0.00% Shs Float2.99B Perf Month-2.49%
Income-1253.00M PEG- EPS next Q0.71 Inst Own17.90% Short Float0.46% Perf Quarter5.24%
Sales44.04B P/S4.48 EPS this Y-96.80% Inst Trans0.61% Short Ratio2.14 Perf Half Y13.02%
Book/sh11.60 P/B5.57 EPS next Y50.76% ROA-1.20% Target Price73.38 Perf Year14.20%
Cash/sh1.60 P/C40.41 EPS next 5Y14.30% ROE-3.30% 52W Range53.63 - 71.70 Perf YTD10.99%
Dividend1.90 P/FCF89.60 EPS past 5Y-50.90% ROI2.00% 52W High-9.83% Beta0.44
Dividend %2.94% Quick Ratio0.70 Sales past 5Y10.20% Gross Margin74.80% 52W Low20.55% ATR1.37
Employees83100 Current Ratio1.00 Sales Q/Q31.00% Oper. Margin-1.20% RSI (14)44.37 Volatility1.34% 1.77%
OptionableYes Debt/Eq0.82 EPS Q/Q-44.70% Profit Margin-2.80% Rel Volume1.12 Prev Close66.30
ShortableYes LT Debt/Eq0.76 EarningsJul 29 BMO Payout- Avg Volume6.36M Price64.65
Recom2.00 SMA20-2.23% SMA50-0.93% SMA2003.95% Volume7,156,649 Change-2.49%
Jun-14-22Downgrade UBS Buy → Neutral
Feb-11-22Upgrade DZ Bank Sell → Hold
Dec-07-21Downgrade Jefferies Buy → Hold
Aug-12-21Resumed JP Morgan Overweight
Apr-12-21Downgrade Argus Buy → Hold
Mar-16-21Upgrade Jefferies Hold → Buy
Feb-25-21Upgrade UBS Neutral → Buy
Jan-15-21Initiated Deutsche Bank Buy
Dec-07-20Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-30-20Upgrade UBS Sell → Neutral
Nov-11-20Upgrade HSBC Securities Reduce → Hold
Sep-29-20Initiated Berenberg Buy
Nov-22-19Initiated SVB Leerink Outperform
Oct-25-19Upgrade Liberum Hold → Buy
Apr-02-19Downgrade UBS Neutral → Sell
Feb-05-19Initiated Exane BNP Paribas Outperform
Jan-25-19Upgrade Shore Capital Hold → Buy
Dec-11-18Resumed Jefferies Hold
Oct-09-18Initiated Guggenheim Buy
Aug-16-18Downgrade Jefferies Buy → Hold
Aug-11-22 03:59AM  
Aug-10-22 04:39PM  
08:14AM  
Aug-09-22 08:43AM  
Aug-08-22 07:37AM  
07:00AM  
06:02AM  
Aug-07-22 09:00AM  
Aug-05-22 08:06PM  
02:20PM  
08:00AM  
07:29AM  
Aug-04-22 02:03PM  
Aug-03-22 12:47PM  
Aug-01-22 11:40AM  
08:48AM  
08:10AM  
Jul-31-22 08:55AM  
Jul-30-22 07:00AM  
06:08AM  
Jul-29-22 04:15PM  
01:46PM  
12:20PM  
11:30AM  
11:18AM  
07:48AM  
06:29AM  
06:04AM  
04:56AM  
03:04AM  
02:22AM  
02:12AM  
Jul-28-22 11:47AM  
Jul-27-22 10:51AM  
Jul-25-22 04:05PM  
11:06AM  
07:00AM  
06:27AM  
Jul-23-22 08:00AM  
Jul-22-22 06:15PM  
10:42AM  
06:18AM  
Jul-21-22 10:40AM  
Jul-20-22 11:08AM  
10:24AM  
Jul-19-22 03:27PM  
01:06PM  
12:46PM  
12:13PM  
12:13PM  
10:00AM  
08:15AM  
Jul-14-22 08:20AM  
Jul-13-22 12:28PM  
08:37AM  
07:32AM  
Jul-12-22 04:01PM  
08:19AM  
Jul-11-22 11:51AM  
Jul-09-22 08:00AM  
Jul-08-22 11:34AM  
Jul-07-22 07:56AM  
Jul-06-22 05:27PM  
04:35PM  
03:28PM  
03:06PM  
09:05AM  
08:01AM  
Jul-05-22 05:16PM  
10:31AM  
10:16AM  
08:16AM  
03:55AM  
03:34AM  
02:41AM  
02:27AM  
02:24AM  
Jul-01-22 06:15PM  
09:00AM  
06:42AM  
04:22AM  
Jun-30-22 04:00PM  
11:07AM  
11:00AM  
07:45AM  
07:00AM  
03:20AM  
Jun-29-22 04:34PM  
01:41PM  
09:17AM  
02:01AM  
Jun-28-22 10:41AM  
Jun-27-22 04:34PM  
01:45PM  
11:04AM  
11:01AM  
10:05AM  
07:34AM  
07:06AM  
06:02AM  
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.